[Effect of continuous renal replacement therapy started at different time on patients with multiple organ dysfunction syndrome].

Abstract

OBJECTIVE:

To explore the effects of continuous renal replacement therapy (CRRT) on serum cytokines and prognosis in multiple organ dysfunction syndrome (MODS) patients based on different therapeutic opportunities.

METHODS:

A total of 34 MODS patients in the treatment of CRRT after admission to ICU of our hospital between July 2008 and October 2010 were recruited. Based on the time interval from the onset of MODS to the initiation of CRRT, the patients were stratified into early group (0 - 3 days, n = 16) and late group (4 - 10 days, n = 18). Both groups of MODS patients received conventional treatment in addition to 72 hours of high-volume hemofiltration (HVHF). The serum levels of such inflammatory mediators as interleukin (IL)-1β, interleukin-1 receptor antagonist (IL-1Ra), IL-6, tumor necrosis factor (TNF)-α, soluble tumor necrosis factor receptor1 (sTNFR1) and IL-10 were detected by enzyme linked immunosorbent assay (ELISA) before CRRT (0 h) and 6, 12, 18, 24, 48 and 72 h during the treatment of CRRT. Dynamic APACHEII scores were also evaluated.

RESULTS:

(1) The early group had lower serum levels of IL-1β, IL-6, IL-10 and higher IL-1Ra, L-1Ra/IL-1β ratio at 72 h than those of 0 h (P < 0.05). And the late group had a declining serum level of IL-1β, IL-6, TNF-α and IL-10 and a rising ratio of IL-1Ra and IL-1Ra/IL-1β during the first 24 h (P < 0.05). As compared with the late group, the early group had a lower level of IL-10 [(25 ± 12) vs (51 ± 33) ng/L] and higher ratios of IL-1Ra and IL-1Ra/IL-1β at 72 h [(1382 ± 899 vs (683 ± 188) ng/L, (54 ± 10) vs (23 ± 6)] (both P < 0.05). (2) The early group had a lower APACHEIIscore than the late group at 0 h (P < 0.05). APACHEII score at 72 h was significantly lower than 0 h in the early group. And there was no obvious change in the late group. There was no statistical difference in the numbers of MODS patients with dysfunctional organs number ≥ 4 at 0 h in both groups. The number of MODS patients with dysfunctional organs number ≥ 4 at 72 h was lower than 0 h in the early group (P < 0.05). And there was no statistical difference in the late group.

CONCLUSION:

Regulating the ratio of anti-inflammatory/pro-inflammatory mediators is critical in the immunomodulation of CRRT. And CRRT may provide more clinical benefits in the early phase (0 - 3 days) of MODS.

• Authors: Li-qun Yao, Zhao-chen Jin, Mu-sen Ji, Chun-ying Xia, Zhi-xin Yu, Jing Liu, Xiu-lan Hu, Jun Yan
• Journal: Zhonghua yi xue za zhi (Zhonghua Yi Xue Za Zhi) Vol. 91 Issue 24 Pg. 1663-7 (Jun 28 2011) ISSN: 0376-2491 [Print] China
• PMID: 21914312 (Publication Type: Clinical Trial, English Abstract, Journal Article)

Chemical References

• Interleukin-1beta
• Interleukin-6
• Tumor Necrosis Factor-alpha
• Interleukin-10

Topics

• Adult
• Aged
• Female
• Humans
• Interleukin-10 (blood)
• Interleukin-1beta (blood)
• Interleukin-6 (blood)
• Male
• Middle Aged
• Multiple Organ Failure (blood, therapy)
• Renal Replacement Therapy (methods)
• Tumor Necrosis Factor-alpha (blood)
• Young Adult